Alliance Pharma plc (LON:APH - Get Free Report)'s stock price reached a new 52-week high during trading on Monday . The stock traded as high as GBX 62.20 ($0.79) and last traded at GBX 61.30 ($0.78), with a volume of 819424 shares changing hands. The stock had previously closed at GBX 61.50 ($0.78).
Analyst Upgrades and Downgrades
Separately, Berenberg Bank cut shares of Alliance Pharma to a "hold" rating and cut their target price for the company from GBX 7,000 ($88.70) to GBX 6,250 ($79.19) in a research note on Wednesday, January 29th.
Check Out Our Latest Stock Analysis on APH
Alliance Pharma Trading Up 0.2 %
The company has a market cap of £327.84 million, a price-to-earnings ratio of -9.76, a PEG ratio of 1.04 and a beta of 0.67. The company has a debt-to-equity ratio of 46.27, a quick ratio of 1.42 and a current ratio of 2.93. The business's 50 day moving average price is GBX 54.87 and its 200-day moving average price is GBX 46.83.
About Alliance Pharma
(
Get Free Report)
Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. The company also offers medicines, medical devices, food supplements, and cosmetics.
Further Reading
Before you consider Alliance Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alliance Pharma wasn't on the list.
While Alliance Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
